Skip to main
LMAT

LeMaitre Vascular (LMAT) Stock Forecast & Price Target

LeMaitre Vascular (LMAT) Analyst Ratings

Based on 5 analyst ratings
Buy
Strong Buy 20%
Buy 40%
Hold 40%
Sell 0%
Strong Sell 0%

Bulls say

LeMaitre Vascular is expected to continue its strong financial performance, with FY/26 revenue growth projected at 12%. Price increases, favorable product mix, and international expansion are expected to drive growth. The increase in dividend and continued focus on profitability and cash flow also contribute to a positive outlook on the company. The current cash balance of $359.1 million and potential for future M&A activities provide further potential for growth.

Bears say

LeMaitre Vascular is facing several challenges that will affect its financial performance, including slower international adoption of its products and potential regulatory delays. The company's heavy reliance on a single product, the mRidium pump, also poses a significant risk to its financial stability. Despite its positive growth in the past, the company's stock may face downward pressure if it cannot effectively diversify its product portfolio and reduce its product concentration risk. Overall, the company's financial outlook for FY/26 may be impacted by these challenges, and it may struggle to meet its revenue and earnings targets.

LeMaitre Vascular (LMAT) has been analyzed by 5 analysts, with a consensus rating of Buy. 20% of analysts recommend a Strong Buy, 40% recommend Buy, 40% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeMaitre Vascular and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeMaitre Vascular (LMAT) Forecast

Analysts have given LeMaitre Vascular (LMAT) a Buy based on their latest research and market trends.

According to 5 analysts, LeMaitre Vascular (LMAT) has a Buy consensus rating as of Apr 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $105.80, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $105.80, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeMaitre Vascular (LMAT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.